Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open1,148.1
High1,149.8
Low1,142
Prev. Close1,149
Avg. Traded Price1,145.32
Volume69,289

MARKET DEPTH

info2
Total bid140105.00
Total ask138412.00
OrdersQtyBid
4361146.3
2511146.2
3101146
2121145.8
71981145.7
AskQtyOrders
1146.57216
1146.6220
1146.7331
1146.87140
1146.9462

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

1099.002 days ago
1119.602 days ago
arrow

LOWER/UPPER CIRCUITS

1001.60
1224.00
arrow
Zydus Lifesciences Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 17.64%, in the last year to ₹27,657.9 Cr. Its sector's average revenue growth for the last fiscal year was 12.14%.
noteAnnual Net Profit,rose 11.37% in the last year to ₹5,040 Cr. Its sector's average net profit growth for the last fiscal year was 1.91%.
notePrice to Earning Ratio,is 22.14, lower than its sector PE ratio of 46.24.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 23.75%
Net profit growth 5Y CAGR : 15.79%

STOCK RETURNS

info
Versus Nifty 50
1 w
-2.39%
vs
-0.32%
1 mth
+1.27%
vs
+0.72%
3 mth
+19.02%
vs
-0.73%
6 mth
+27.70%
vs
-4.2%
1 yr
+17.09%
vs
-4.85%
3 yr
+83.68%
vs
+21.53%
5 yr
+83.06%
vs
+51.34%
Zydus Lifesciences Ltd Top mutual funds holding
arrow

About Zydus Lifesciences Limited

 

Zydus Lifesciences Limited is an India-headquartered lifesciences company with two integrated businesses: pharmaceuticals and consumer health and wellness . The company operates a network of 39 manufacturing facilities globally, 16 of which are USFDA inspected, underscoring its scale and quality focus; capabilities span oral solids, injectables, nasals, topicals, transdermal patches, and biologics including monoclonal antibodies and antibody–drug conjugates . Its global footprint is reflected in FY25 revenue from operations of Rs 232,415 million, with contributions from India (Rs 92,530 million), the US (Rs 111,411 million), and other markets (Rs 28,474 million). 

 

A brief capital history dates back to May 15, 1995 (first equity allotment), with an Initial Public Offer (IPO) in February–March 2000, marking key milestones in its evolution . The company positions manufacturing as a strategic capability to deliver safe, effective and affordable medicines worldwide.

 

Zydus Lifesciences Limited’s Business Segments

  • Pharmaceuticals: An integrated operation spanning research, development, production, marketing and distribution of pharmaceutical products. The portfolio includes Active Pharmaceutical Ingredients (API), human formulations, and animal health and veterinary products. FY25 segment revenue: Rs 205,439 million.
  • Consumer Products: Development, production, marketing and distribution of differentiated health and wellness products. FY25 segment revenue: Rs 26,976 million.

 

Zydus Lifesciences Limited Key Management

  • Pankaj R. Patel, Chairman
  • Dr. Sharvil P. Patel, Managing Director
  • Nitin D. Parekh, Chief Financial Officer

 

Latest Updates on Zydus Lifesciences Limited

  • Strategic acquisition: The company announced plans to acquire 100% of Amplitude for a total consideration of Euro 300 million, subject to regulatory approvals; the simplified cash tender offer filing with the French AMF is expected after approvals, with completion of the block acquisition and filing targeted by end-December 2025.
  • R&D and technology: Zydus invested Rs 11,838.00 million in R&D in FY25 and imported/absorbed multiple manufacturing technologies; capital investment during the year was Rs 267.87 million.
  • Sustainability and energy: The company advanced renewable energy use, including >1,000 MWh in-house solar generation, >80,000 MWh hybrid renewable power purchases, and >40,000 MT biomass fuel usage, to reduce environmental impact.
  • CSR impact: Total CSR spend in FY25 was Rs 640.01 million. Initiatives included “Green Gujarat 2.0,” engaging over 15,000 employees and 12,000 students to create 1.34 lakh native seed balls dispersed by drone in Gandhinagar.
  • Recognitions: Honors included Responsible Business of the Year 2024 (SABERA), “Most Innovative and Inventive Lifesciences Company of the Year 2024,” multiple communications awards for the “Easiest Exam” breast cancer awareness campaign, and Fortune India’s “India’s Best CEOs of 2024” (health and lifesciences) for the Managing Director.
personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

The all-time high (ATH) for Zydus Lifesciences Ltd was ₹1,300.90, recorded on 09 Aug 2024. At the current price of ₹1,111.80, the stock is trading 14.54% below its all-time high. The all-time low recorded was ₹86.21 on 22 Jan 2010.

Yes,Zydus Lifesciences Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 23.50 per share between FY2022 and FY2026, with the most recent dividend of ₹1.00 per share for May 26, with an ex-dividend date of 24 Jul 2026. At the current market price of ₹1,111.80, the trailing dividend yield of Zydus Lifesciences Ltd stands at 12.00%.

Over the last 6 months, Zydus Lifesciences Ltd has given a return of 24.11%. The stock was priced at ₹893.35 on 27 Jan 2026 and has Rise to ₹1,111.80 as of 25 Jul 2026, a change of ₹218.45 per share.

Zydus Lifesciences Ltd has delivered a 83.09% absolute return over the past 5 years, equivalent to a CAGR of 12.86% per annum. The stock was priced at ₹607.24 in Jul 2021 and has risen to ₹1,111.80 as of 25 Jul 2026. An investment of ₹1,00,000 in Zydus Lifesciences Ltd five years ago would be worth ₹1,83,090.00 today.

For Q4 FY26, Zydus Lifesciences Ltd reported: Revenue (Net Sales): ₹43888.00 Cr - Up 92.19% year-on-year from ₹22836.00 Cr in Q3 FY26. Net Income (PAT): ₹17220.00 Cr - Up 480.78% year-on-year from ₹2965.00 Cr in Q3 FY26.

Zydus Lifesciences Ltd has delivered 13.55% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,181.50 on 08 Jul 2026 and a 52-week low of ₹835.50 on 02 Apr 2026. It is currently trading at ₹1,111.80 as of 25 Jul 2026.

Zydus Lifesciences Ltd has delivered a return of 17.99% over the last 3 months. The stock was trading at ₹927.40 on 24 Apr 2026 and is currently at ₹1,111.80 as of 25 Jul 2026, reflecting a Gain of ₹184.40 per share over this period.

The intraday high for Zydus Lifesciences Ltd on the NSE today (25 Jul 2026) was ₹1,129.00. This compares to the 52-week high of ₹1,181.50 recorded on 08 Jul 2026. Today's high was -4.44% below the 52-week high.

The intraday low for Zydus Lifesciences Ltd on the NSE today was ₹1,099.00. The stock's 52-week low stands at ₹835.50, recorded on 02 Apr 2026. Today's low is 31.54% above the 52-week low, indicating the stock is trading well above its yearly lows.

As of 25 Jul 2026, the share price of Zydus Lifesciences Ltd is ₹1,111.80 on the NSE and ₹1,103.00 on the BSE. The stock opened at ₹1,109.00, touched a high of ₹1,129.00 and a low of ₹1,099.00 during today's session.

+91
Offer Banner Trigger
Offer Banner

Open a FREE Demat Account

+91